A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Launched by ALNYLAM PHARMACEUTICALS · Dec 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ALN-TTRSC04, which is being tested for its safety and how well it works in healthy volunteers. The main goal is to find out how the body handles this treatment and to see if it's safe to use. The trial is currently looking for participants aged between 18 and 75 years, and anyone interested must have a body mass index (BMI) within a specific range (between 18.0 and 30.0).

Participants in this trial will receive single doses of the treatment and will be monitored closely to check for any side effects or reactions. It's important to note that individuals with certain health conditions, like kidney issues or elevated liver enzymes, will not be eligible to participate. If you or someone you know fits the eligibility criteria and is looking for new treatment options, this could be an opportunity to contribute to research in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Body mass index (BMI) ≥18.0 kg/m\^2 and ≤30 kg/m\^2 assessed at Screening.
• Exclusion Criteria:
• • Has an estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73m\^2 at screening.
• • Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct bilirubin above the upper limit of normal (ULN).

Trial Officials